Attana (ATANA) Q2 2026 earnings summary

Executive summary

• Focused on biosensor development, consumables, and contract research in biotech and pharma sectors.

• Strategic initiatives included a CRO pilot with Offspring Biosciences and patent commercialization efforts.

• Strengthened commercial presence in the UK and extended key customer agreements.

• Evaluating structural partnerships and strategic alternatives to enhance market position.

Financial highlights

• Net sales for Jan–Jun 2026 were 0.17 MSEK, down from 0.31 MSEK year-over-year.

• Operating result improved to -3.31 MSEK from -3.93 MSEK year-over-year, despite lower sales.

• Result after tax was -1.74 MSEK compared to -0.37 MSEK year-over-year.

• Total revenue for Q2 2026 was 0.63 MSEK, up from 0.39 MSEK in Q2 2025.

• Rights issue raised approximately 13.45 MSEK before costs.

Outlook and guidance

• Emphasis on increasing sales, recurring revenues, and strategic collaborations.

• Lower cost base and strengthened financial platform expected to support commercial initiatives in H2 2026.